Re: Past Weeks
Pretty tough indeed, down $14 in 7 trading days and getting crushed by the XBI and IBB in the last two days in the complete absence of company specific news. The old hands here are used to this, but it is annoying. Q2 calls have been Neurocrine's best, hopefully we will have a repeat. GL.